A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC) (CHIARA)

Clinical Trial ID NCT01562015

Rank	Title	Journal	Year	PubWeight™‹?›
1	A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.	Clin Cancer Res	2013	1.90
2	Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions.	Expert Opin Investig Drugs	2014	1.21
3	Molecular pathways and therapeutic targets in lung cancer.	Oncotarget	2014	1.16
4	Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical β-propeller domain.	Proc Natl Acad Sci U S A	2014	0.98
5	A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer.	Front Oncol	2014	0.93
6	ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it.	Transl Lung Cancer Res	2014	0.89
7	Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies - Past, Present, and Future.	Front Oncol	2014	0.82
8	Targeting EML4-ALK driven non-small cell lung cancer (NSCLC).	Transl Lung Cancer Res	2013	0.81
9	Clinical use of crizotinib for the treatment of non-small cell lung cancer.	Biologics	2013	0.80
10	Hsp90 inhibitors in oncology: ready for prime time?	Curr Oncol	2014	0.80
11	Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program.	Pediatr Blood Cancer	2013	0.78
12	Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy.	Ther Adv Med Oncol	2015	0.76